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Anamaria A. Camargo2
We report the results of a transcript finishing initiative, undertaken for the purpose of identifying and characterizing
novel human transcripts, in which RT-PCR was used to bridge gaps between paired EST clusters, mapped against the
genomic sequence. Each pair of EST clusters selected for experimental validation was designated a transcript finishing
unit (TFU). A total of 489 TFUs were selected for validation, and an overall efficiency of 43.1% was achieved. We
generated a total of 59,975 bp of transcribed sequences organized into 432 exons, contributing to the definition of
the structure of 211 human transcripts. The structure of several transcripts reported here was confirmed during the
course of this project, through the generation of their corresponding full-length cDNA sequences. Nevertheless, for
21% of the validated TFUs, a full-length cDNA sequence is not yet available in public databases, and the structure of
69.2% of these TFUs was not correctly predicted by computer programs. The TF strategy provides a significant
contribution to the definition of the complete catalog of human genes and transcripts, because it appears to be
particularly useful for identification of low abundance transcripts expressed in a restricted set of tissues as well as for
the delineation of gene boundaries and alternatively spliced isoforms.
[Supplemental material is available online at www.genome.org. The sequence data from this study have been
submitted to GenBank under accession nos. CF272536–CF272733.]
A primary objective of the Human Genome Project has been the
identification of the complete set of human genes and their de-
rived transcripts. A major step towards this goal was achieved at
the beginning of 2001 with the publication of two independent
draft versions of the human genome sequence and the identifi-
cation of >30,000 genes (Lander et al. 2001; Venter et al. 2001).
However, it became apparent that extracting exonic sequences
directly from the human genome is not straightforward and that
a variety of complementary strategies are required for gene iden-
tification and characterization.
In this context, microarrays (Penn et al. 2000; Dennis 2001;
Schoemaker et al. 2001; Kapranov et al. 2002) and sequence com-
parisons with other organisms at an appropriate evolutionary
distance (Batzoglou et al. 2000; Roest et al. 2000) constitute pow-
erful preliminary approaches to identifying transcribed regions
within the genome sequence. Nevertheless, transcript sequenc-
ing is necessary both for the final proof of the existence of an
expressed gene and for the precise identification of intron/exon
boundaries and alternatively spliced forms (Camargo et al. 2002).
A full-length cDNA sequence, ideally including a transcrip-
tion initiation site and a polyadenylation site, is the gold stan-
dard for transcript definition. Considerable progress has been
made in the generation of representative full-length cDNA se-
quences (Strausberg et al. 1999, 2002; Wiemann et al. 2001;
Kikuno et al. 2002; Nakajima et al. 2002), especially following the
development of sophisticated protocols for obtaining full-length
transcript molecules and to correct for transcript expression bias
(Bonaldo et al. 1996, Carninci et al. 2000).
Expressed sequence tags (ESTs) are another major source of
transcript sequence. ESTs either are single-pass, partial sequences
derived either from the 5 and 3 extremities of cDNA clones
(Adams et al. 1991) or are specifically directed towards the central
coding regions of transcripts, in the case of open reading frame
ESTs (ORESTES; Dias et al. 2000; Camargo et al. 2001). Initially,
ESTs were exploited as a source for gene discovery (Adams et al.
1992, 1993), but they have also been widely used to build tissue-
specific transcript profiles (Bortoluzzi et al. 2000a,b,c; Hu-
miniecki and Bicknell, 2000; Phillips et al. 2000; Yu et al. 2001;
Katsanis et al. 2002; Megy et al. 2003), to construct gene-based
physical maps (Hudson et al. 1994), to compare genomes of dif-
ferent organisms (Tugendreich et al. 1994; Lee et al. 2002), to
accurately identify transcripts in genomic sequences (Bailey et al.
1998; Jiang and Jacob 1998; Kan et al. 2001), and to study aspects
of mRNA structure, such as splicing variants (Hide et al. 2001;
Modrek et al. 2001; Clark and Thanaraj 2002; Kan et al. 2002; Xie
et al. 2002; Xu et al. 2002; Wang et al. 2003), alternative poly-
adenylation (Gautheret et al. 1998; Beaudoing and Gautheret
2001; Iseli et al. 2002), and single nucleotide polymorphisms
(Garg et al. 1999; Picoult-Newberg et al. 1999; Clifford et al. 2000;
Irizarry et al. 2000; Hu et al. 2002).
To date, >5,200,000 human ESTs have been generated from
different organs and tissues, deriving mainly from the Merck
Gene Index Project (Williamson 1999), the Cancer Genome
Anatomy Project (CGAP; Strausberg et al. 2000), and the Human
Cancer Genome Project Ludwig/FAPESP (HCGP; Dias et al. 2000;
Camargo et al. 2001). Nevertheless, it is widely recognized that
EST databases are subjected to artifacts related to the partial, low-
quality nature of the sequences and the presence of various kinds
of contamination (Sorek and Safer 2003). In addition, because of
the large differences in abundance between RNA species, the cov-
erage of individual transcripts by ESTs is highly variable. Despite
that, it is believed that the vast majority of transcripts have been
sampled at least once by either a full-length cDNA or EST se-
quence (Ewing and Green 2000; Liang et al. 2000).
Although the amount of transcript data currently available
is not sufficient to identify all human genes, the judicious use of
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this data set, in conjunction with the draft sequences of the hu-
man genome, has been highly informative in the characteriza-
tion of new human genes (Reymond et al. 2002; Silva et al. 2003).
Here we describe the utilization of a transcriptome database to
guide the generation of novel human transcript sequences on a
genome-wide basis. By using the genomic sequence as a scaffold
for EST mapping and clustering, we have used RT-PCR to bridge
gaps between EST clusters that we judged as likely to be derived
from the same genes. The resulting novel sequence confirms that
the ESTs from different clusters are, in fact, derived from a com-
mon transcript and defines the intervening region between
them.
Because this process is very similar to the finishing phase of
genome projects, we called it transcript finishing (TF). This pow-
erful, albeit laborious, approach allows the characterization of
novel human transcripts and splicing isoforms, which appear to
be generally expressed at a low abundance level and/or in a re-
stricted set of tissues and avoids the necessity of a full-length
cDNA clone in order to confirm the structure of a gene.
RESULTS
Generation of the Transcriptome Database and EST
Cluster Selection for Experimental Validation
We have used the publicly available human genome and tran-
script sequences to identify and experimentally validate addi-
tional transcribed regions in the human genome. The two data
sets were integrated into the transcriptome database by using the
BLASTN program to map all transcript sequences onto the as-
sembled version of the human genome available from the Na-
tional Center for Biotechonology Information (NCBI). We have
also mapped to the genome, using the raw data generated by EST
sequencing projects, a set of trusted 3tags that provide unique
identifiers for transcript 3 ends (Iseli et al. 2002). The tags were
used for positional orientation and as a start point for transcript
reconstruction. To facilitate visualization of the alignments and
the access to information such as project and tissue source of the
sequences, alignment scores, and the position of 3tags, a graphi-
cal interface was also developed (Fig. 1).
We identified 244,148 human transcript clusters, of which
14,598 contained at least one full-length cDNA sequence, and
229,550 clusters that were composed exclusively of partial tran-
script sequences. Of the set of 14,598 clusters containing full-
length sequences, 13,149 (90%) had at least one corresponding
EST, and the remaining 1449 (10%) were composed only of full-
length cDNA sequences. These data demonstrate that, despite the
fact that >5 million EST sequences are available, they do not fully
cover the human transcriptome and that the generation of addi-
tional transcribed sequences is still required.
It is noteworthy that clusters composed exclusively by ESTs
have a reduced number of sequences (average, 5.9 sequences)
derived from fewer different tissues (average, 3.0), compared with
clusters containing a full-length cDNA, which have an average of
Figure 1 TFI graphical interface. The TFI graphical interface displays a region of the human genome sequence as a yellow line, with a scale in base
pairs (bp). Expressed sequence tags (ESTs) that align with the genome sequence are shown in different colors, depending on the project of origin:
ORESTES from the FAPESP/LICR Human Cancer Genome Project in purple; CGAP in green, MGC in blue, and TFI in yellow, with splicing structures
represented as gray lines. The interface shows an experimentally validated TFU (number 171) joining two EST clusters. The TFI interface also provides
information on the tissue of origin of the transcript sequences, the percentage of similarity of each exon with the human genome sequence, and the
presence of 3 tags represented as green triangles.
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65.5 sequences derived from eight different tissues. Based on
these observations, we conclude that the human transcripts that
remain to be defined are expressed at low levels in a restricted set
of tissues and that their characterization will benefit from a direct
approach such as the TF.
Because EST databases contain a significant fraction of arti-
factual and contaminant sequences, we selected, for experimen-
tal validation, pairs of clusters that consist of ESTs that align
noncontiguously to the genome, consistent with the presence of
a splicing structure. We also restricted our validation to pairs of
clusters that map at a maximum distance of 10 kb from each
other, in order to increase the probability that these clusters be-
long to the same transcript. By using these criteria, a total of 2373
pairs of clusters (∼2% of the total number of clusters composed of
partial sequences) were initially selected and subjected to manual
inspection using our graphical interface.
Manual inspection allowed the assessment of similarity and
extension of the alignments, as well as the position of the se-
lected pair of clusters relative to the 3’tags. Following this proce-
dure, a subset of 489 pairs of clusters was initially selected for
experimental validation. The number of clusters eliminated by
manual inspection was very low; therefore, the 489 pairs of clus-
ters selected for experimental validation can be considered an
unbiased sample of the 2373 initially selected clusters. Clusters
selected for validation were separated from each other by an av-
erage 2879 bp of intervening genomic sequence and were com-
posed by an average of 5.92 EST sequences derived from an av-
erage of three distinct tissues. Each pair of EST clusters selected
for experimental validation was designated as a single TF unit
(TFU). Information related to the 489 TFUs selected for validation
can be accessed at http://200.18.51.201/viewtfi.
Experimental Validation and the Generation of New
Transcribed Sequences
A general overview of the computational and experimental vali-
dation strategies is presented in Figure 2. A total of two coordi-
nation groups, four bioinformatics groups, and 29 validation
laboratories, linked through the Internet, participated in the
computational and experimental phase of the project (http://
200.18.51.201/transcript/Participants.html). Following cluster
selection and manual inspection, primers for RT-PCR validation
of each TFU were designed automatically. The genomic sequence
was chosen as a template for primer design because it is generally
of a higher quality than are EST sequences. cDNA preparation
was also a critical issue, because both the quality and the repre-
sentation of different tissues directly influence the validation ef-
ficiency. As an indicator of genomic DNA contamination, the
total RNA preparations were subjected to PCR amplification by
using primers within intronic sequences flanking the exon 12 of
the MLH1 gene and found to be negative. The quality of the
cDNA product was demonstrated by PCR amplification of se-
quences located at the 5 extremity of the NOTCH2 transcript (a
long transcript of 11.4 Kb). A total of 22 cDNA preparations,
derived from a number of cell lines and representing 18 distinct
tissues, were used.
The total of 3019 sequences, generated during the project,
was subjected to an automated cleaning protocol. High-quality
sequences were aligned against the genomic sequence, and the
alignment coordinates and scores for validated sequences were
loaded into the transcriptome database and displayed on the
graphical interface (Fig. 1). We successfully validated 211 of the
489 TFUs that were distributed, yielding an overall validation
efficiency of 43.1%.
A single pair of primers was tested for each TFU, and experi-
mental validation was undertaken in a high-throughput single-
pass format. Few modifications were adopted when a positive
amplification was not achieved (see Methods). To estimate the
false-negative amplification rate of the TF strategy, we deter-
mined the number of the nonvalidated TFUs for which a full-
length cDNA sequence had been made available by other se-
quencing projects during the course of our project. For 40 of the
nonvalidated TFUs, we were able to identify a full-length se-
quence linking the two EST clusters initially
selected for validation. Thus, these cases
can be considered to be false-negative am-
plifications. For 118 of the nonvalidated
TFUs, the existence of a full-length se-
quence matching just one of the two se-
lected clusters allowed us to conclude that
the two clusters were in fact part of differ-
ent transcripts. For these cases, the absence
of an RT-PCR product thus reflects true
negatives. For the 120 of the remaining
nonvalidated TFUs, a conclusive result
could not identify any corresponding full-
length sequence. Therefore, based on these
results, we can estimate that the rate of
false-negative amplifications in the TF strat-
egy is ∼25% (40/158 nonvalidated TFUs).
In addition, to identify variables re-
lated to the expression pattern of the novel
transcripts that influence the efficiency of
validation, two sets composed of 174 vali-
dated TFUs and 208 nonvalidated TFUs
were compared. As shown in Table 1, the
validated TFUs had, on average, more ESTs
in each cluster derived from a larger num-
ber of different tissues. Both of these differ-
ences were statistically significant accord-
ing to Mann-Whitney tests, indicating that
a higher expression level and a broader ex-
pression pattern of the selected transcripts
Figure 2 General scheme of the TFI strategy. Schematic outline of the strategy used for compu-
tational and experimental validation of TFU sequences. Following the development of bioinformat-
ics tools, the generation of the transcriptome database, and automatic cluster selection, the project
tasks were divided between the coordination and the validation laboratories.
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favored validation. The presence of ESTs derived from the same
tissue in both clusters did not influence the likelihood of valida-
tion according to 2 tests.
A total of 59,975 bp of transcribed sequence, organized into
432 exons, were generated, contributing to the definition of the
structure of 211 distinct human transcripts. Each validated TFU
had a mean of 281.6 bp and a median of 207 bp of novel se-
quence not represented by the original EST clusters and a mean
of 2.03 and a median of two newly defined exons. The validated
TFU sequences have been submitted to GenBank under the ac-
cession numbers CF272536 to CF272733, which are provided as
Supplemental Table 1.
Consensus Sequences Generation and Annotation
of the Validated Human Transcripts
Consensus sequences produced by assembling the sequences de-
rived from the validation fragment and the sequences from all
ESTs in both clusters were obtained for 186 of the 211 validated
TFUs. Assembly of a consensus sequence was not possible for
25 TFUs, due mainly to the presence of repetitive sequences
and alternative splicing forms. Consensus sequences, with an
average of 1240 bp, can be accessed at (http://200.18.51.201/
viewconsensus/).
Consensus sequences derived from the validated TFUs were
aligned to the July 2003 version of human genome sequence
assembly provided by the University of California, Santa Cruz
(UCSC), using the BLAT search tool (http://genome.ucsc.edu/cgi-
bin/hgBlat) to compare the validated consensus sequences with
known genes and gene predictions (Table 2). A significant frac-
tion (68.8%) of the validated transcripts completely overlapped
with the alignment coordinates of a known gene or full-length
human mRNA submitted to the GenBank during the course of
our project (Fig. 3A), and a smaller fraction (10.2%) represented
extensions (mostly 5) to partial cDNA sequences deposited in
public databases (Fig. 3B). However, for 21% of the validated
TFUs, a full-length cDNA sequence was not available in public
databases as of July 2003. The structure of the majority (69.2%) of
the validated TFUS without a corresponding full-length cDNA
sequence had not been correctly predicted by ab initio gene pre-
diction programs such as Fgenesh++, Geneid, and GenScan.
These TFUs can thus be considered as new human transcripts.
The consensus sequences corresponding to new human
transcripts were further characterized by BLASTX analysis, and
protein domains were predicted by using the Pfam and Prosite
databases. Of the 39 consensus sequences representing new hu-
man transcripts, 27 (69.2%) contained an ORF of at least 100
amino acids, and eight (20.5%) contained a clearly defined pro-
tein domain including three IG-like domains and a protein ki-
nase. Complete information on the characterization of the vali-
dated TFUs, including consensus size, annotation, chromosomal
location, and expression pattern based on ESTs distribution, are
provided as Supplemental Table 2.
The validated transcripts that completely overlapped with
the alignment coordinates of a known gene containing a defined
ORF were used to estimate the percentage of consensus sequences
that represent complete transcripts. Only a small fraction (9.7%)
of the 93 validated TFUs analyzed contained a complete ORF.
The low percentage obtained was expected because, in the TF
strategy, RT-PCR is used to brigde gaps between partial transcript
sequences.
Identification and Experimental Validation
of Alternatively Spliced Isoforms
Several reports have suggested that at least 30% to 35% of human
genes undergo alternative splicing (Brett et al. 2000; Modrek et al.
2001); nevertheless, this value is probably underestimated be-
cause many cell types have not yet been fully explored by cDNA
sequencing. The use of different cDNA sources during the experi-
mental validation phase of the new human transcripts allowed us
to identify many new splicing variants. We explored the degree
of sequence variability due to alternative splicing in the set of
186 consensus sequences that we generated and found evidence
for alternative splicing in 22 (12%) cases (Table 3). Intron reten-
tion was observed in 11 TFUs, and alternative exon usage was
detected in 11 of the 22 TFUs with alternative splicing. Con-
served GT-AG splice junctions were present in all TFUs with al-
ternative exon usage. The possibility of genomic DNA contami-
nation, in those cases in which we have observed the retention of
an intron, was excluded due to the presence of processed introns
in the same cDNA molecule containing the retained intron.
Moreover, the RNAs used for experimental validation of the al-
ternatively spliced forms have been treated with DNase and
tested for the absence of intronic sequences, as described in
Methods.
We selected six TFUs with alternative exon usage, represent-
ing a total of 14 splicing isoforms, for further experimental vali-
dation. Each pair of primers used for experimental validation of
the alternatively spliced forms was assayed against all 22 cDNA
sources, without pooling. Touchdown PCR confirmed 10 (83%)
of the putative investigated isoforms. No PCR amplification was
achieved for one TFU. Some splicing isoforms were expressed in
Table 1. Comparison Between Validated and Nonvalidated TFUs
Validated TFUs
(Std deviation)
Nonvalidated TFUs
(Std deviation) P value
Average distance between clusters 2609 (3202) 3105 (2942) 0.008
Average no. of ESTs in each cluster 6.10 (8.91) 5.77 (13.23) 0.010
Average no. of distinct tissues in each cluster 3.45 (4.27) 2.85 (4.54) 0.002
Presence of a common tissue in both clusters Yes 63 Yes 62 0.223
No 111 No 146
Table 2. Annotation of Validated Consensus
Categories
Number of
consensus
sequences
Percentage
(%)
Known gene 128 68.8
Extension of a known gene 19 10.2
New transcript w/total prediction 12 6.5
New transcript w/partial prediction 15 8.0
New transcript w/o prediction 12 6.5
Total 186 100
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a restricted pattern, being detected in one or a few of the tissues
analyzed by RT-PCR (data not shown). None of these splicing
isoforms had been previously identified, highlighting the poten-
tial use of the TF strategy for uncovering the genetic variability
generated at the transcriptome level.
A typical example of this experimental validation is illus-
trated in Figure 4. In this case, we were able to identify two
alternative exons, one of which presents an extra exon of 138 bp
and the other a 21-bp extension of an exon already represented
by EST sequences. The possible combination of these variants
results in four splicing isoforms. Figure 4 shows a 388-bp product
(obtained with primers P1 and P2) corresponding to the proto-
type isoform, a 370-bp product (primers P2 and P3) correspond-
ing to the isoform containing the additional exon, a 314-bp
product (primers P1 and P4) corresponding to the isoform with
the extended exon, and a 452-bp product corresponding to the
isoform containing both the additional exon and the extended
exon.
DISCUSSION
Currently, intense activity is directed toward defining the com-
plete set of genes and their derived transcripts in the human
genome. This information will have a profound impact in diverse
areas of biology such as human evolution, structural genomics,
and medicine. However, because of the highly dispersed and
complex structure of human genes, it is extremely difficult to
correctly identify transcribed regions within the genome (Ca-
margo et al. 2002).
Estimates based on gene prediction both within individual
finished chromosomes (Dunham et al. 1999; Hattori et al. 2000),
as well as in the draft human genome sequences (Lander et al.
Figure 3 Characterization and annotation of validated TFUs. Alignment of four consensus sequences, derived from the validated TFUs, to the July 2003
version of the UCSC human genome sequence assembly, using the BLAT search tool. (A) TFU00023 corresponds to YourSeq (black) completely
overlapping with known genes based on SWISS-PROT, TrEMBL, mRNA, and RefSeq (dark blue). (B) TFU01102 represents a 5 extension of a partial cDNA
(FLJ23834). (C) TFU01013 represents a new human transcript structure that was correctly predicted by ab initio gene predition transcripts, such as
Fgenesh++ (green). (D) TFU00125 represents a new human transcript with no predicted transcripts described by gene prediction programs.
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2001; Venter et al. 2001), have uniformly concluded that the
human genome possesses <35,000 genes. This number has been
supported by a preliminary analysis of EST coverage of known
genes (Ewing and Green 2000) as well as comparative genomics
analysis (Roest et al. 2000). Most of these 35,000 genes are al-
ready represented by a full-length cDNA sequence in transcript
databases. In UniGene (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=unigene), for example, there are currently 28,412
transcript clusters represented by at least one full-length cDNA
sequence.
Here we have proposed and validated the use of the TF strat-
egy for characterization of new human transcripts that are only
partially represented by ESTs. Because EST databases contain a
significant fraction of artifactual and contaminant sequences, we
selected pairs of clusters for experimental validation that exhib-
ited a clear splicing structure when aligned to the genome. By
requiring the occurrence of splicing, the level of contamination
in the EST databases is significantly reduced, although at the
expense of eliminating many genuine 3 ESTs. The selection cri-
teria used in our initial analysis are very restrictive, and the adop-
tion of less stringent criteria (including clusters without a splic-
ing structure) will certainly be required to complete the catalog of
human genes using the strategy we described. Given the 2373
initially selected clusters, of which 489 were subjected to experi-
mental validation, 1884 pairs of clusters remain to be validated.
If we assume an overall validation efficiency of 43%, we can
estimate that the TF strategy might contribute to the definition
of at least 791 additional genes in the human genome.
Several factors may have influenced our validation effi-
ciency, including experimental limitations related to primer and
cDNA synthesis, the particular characteristics of human tran-
scripts such as low expression level, and the existence of a sig-
nificant proportion of sense-antisense transcriptional units on
opposite DNA strands of the same genomic locus (Yelin et al
2003). A 25% false-negative amplification rate was estimated for
the TF strategy and is probably related to the high-throughput
single-pass format adopted for the experimental validation. In
this context, the use of additional primer pairs and modifications
of cycling parameters that would favor the amplification of dif-
ficult targets could be added to the process to reduce the negative
amplification rate.
We found that validation efficiency was enhanced by imple-
mentation of quality controls for cDNA synthesis, the use of
polyA+-derived cDNA, a combination of both oligo dT and ran-
dom primers for cDNA synthesis, and also the use of nested RT-
PCR. We also observed that validated pairs of clusters had a
higher average number of ESTs per cluster and a higher number
of different tissues represented by the clusters compared with
pairs of clusters that we were not able to validate. Validated TFUs
had, on average, 6.1 ESTs in each cluster derived, on average,
from 3.45 distinct tissues. Noteworthy, in 41% of the validated
TFUs, one of the two EST clusters was composed of a single EST,
and in 13% of the cases, both clusters corresponded to singleton
ESTs, indicating the often overlooked importance of this kind of
data.
For a reasonable fraction (21%) of the validated TFUs, a full-
length cDNA sequence was not yet available in public databases.
The structure of the majority (69.2%) of these validated TFUs had
not been correctly predicted by ab initio gene prediction pro-
grams and, consequently, was not annotated in the human ge-
nome. In addition, the use of different cDNA sources in the vali-
dation process allowed us to identify many splicing variants that
were further validated by RT-PCR. As for 21% of validated se-
quences, none of these splicing variants had been previously
identified.
We conclude that the TF strategy provides a convenient and
unique means for delineating gene boundaries and new tran-
scribed sequences. The TF strategy permits the characterization of
new human transcripts and splicing isoforms expressed at a low
level and in a restricted set of tissues and will certainly continue
to contribute to the definition of the complete catalog of human
genes and transcripts.
METHODS
Cell Culture
Human cell lines were obtained from the American Type Culture
Collection (ATCC) and cultured as recommended (http://
www.atcc.org). The following cell lines were used in order to
generate a cDNA panel representing different tissues: A172 glio-
blastoma; T98G multiform glioblastoma; FaDu squamous cell
carcinoma; SW480 colorectal adenocarcinoma; Skmel-25 malig-
nant melanoma; DU145 prostate carcinoma; HeLa cervix adeno-
carcinoma; XP Xeroderma pigmentosum fibroblasts; ZR-75-1,
MCF-7, and Hs578T breast ductal carcinoma; IM9 B transformed
lymphoblasts; TT thyroid carcinoma; U937 histyocytic lym-
phoma; Hs1.Tes normal testis; Hs732.PL normal placenta; Hep
G2 hepatocarcinoma; NCI-H1155 and H358 lung carcinoma;
SCaBER urinary bladder carcinoma; SAOS 2 osteosarcoma; and
Tu-rim primary culture of a kidney tumor.
RNA Extraction and cDNA Synthesis
Total RNA was prepared from cultured cells seeded in four 150-
mm-diameter (P150) plates by using the cesium chloride cushion
technique (Chirgwin et al. 1979). Poly A+ RNA was isolated from
200 µg total RNA with the PolyAttract mRNA isolation kit (Pro-
mega), and the total yield of this purification was used for cDNA
synthesis. For cDNA synthesis, 100 to 200 µg total RNA or the
corresponding purified mRNA were treated with 100 U DNAse I
(FPLC-pure, Amersham) and reverse-transcribed by using oli-
go(dT)12-18, random primer and SuperScript II (Invitrogen), fol-
lowing the manufacturer’s instructions. The resulting cDNA was
then subjected to RNase H treatment and distributed among the
Table 3. Alternative Splicing Forms Within Validated TFs
Validated
consensus
Type of
alternative
splicing
Presence of
conserved
acceptor
and donor
sites
No. of
alternative
isoforms
No. of
validated
isoforms
TFU0118 Exon usage Yes 2 1
TFU0200 Exon usage Yes 4 4
TFU0274 Exon usage Yes 2 2
TFU0351 Exon usage Yes 2 2
TFU1004 Exon usage Yes 2 1
TFU1058 Exon usage Yes 3 0
TFU0155 Exon usage Yes 2 nd
TFU0238 Exon usage Yes 2 nd
TFU0308 Exon usage Yes 2 nd
TFU0003 Intron retention nd nd nd
TFU0019 Intron retention nd nd nd
TFU0035 Intron retention nd nd nd
TFU0052 Intron retention nd nd nd
TFU0099 Intron retention nd nd nd
TFU0112 Intron retention nd nd nd
TFU0125 Intron retention nd nd nd
TFU0131 Intron retention nd nd nd
TFU0209 Intron retention nd nd nd
TFU0285 Intron retention nd nd nd
TFU0371 Intron retention nd nd nd
TFU0148 Exon skipping nd nd nd
TFU1061 Exon skipping nd nd nd
nd = not done.
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31 validation laboratories involved in the project. The quality of
the cDNA synthesis and the absence of genomic DNA contami-
nation were evaluated for each preparation. Total RNA was sub-
jected to PCR amplification by using primers within intronic se-
quences flanking exon 12 of the MLH1 gene (forward, 5-
TGGTGTCTCTAGTTCTGG-3; reverse, 5-CATTGTTGTAG
TAGCTCTGC-3). The quality of the cDNA product was also
tested by PCR amplification of sequences located at the 5 ex-
tremity of the NOTCH2 transcript (a long transcript of 11.4Kb;
forward, 5-ACTGTGGCCAACCAGTTCTC-3; reverse, 5- CTCT
CACAGGTGCTCCCTTC-3).
RT-PCR and Sequencing
RT-PCR was carried out in 25 µL reaction mixtures containing 1
µL cDNA, 10 Taq DNA polymerase buffer, 200 µM dNTP, 6
pmoles of primers, 1.5 mM MgCl2, and 1 U Taq DNA polymerase
(GIBCO BRL). Standard PCR conditions were as follows: 4 min at
94°C (initial denaturation), 40 sec at 94°C, 40 sec at 55°C, and 1
min at 72°C for 35 cycles and a final extension step of 10 min at
72°C. Modifications of the standard protocol included annealing
temperature, MgCl2 concentration, addition of PCR enhancers
such as betaine, and the use of polymerases with hot start activ-
ity. PCR products were directly sequenced with the same primers
used for RT-PCR or cloned before sequencing. If more than one
fragment was obtained for the same TFU using different cDNA
sources, all fragments were sequenced. This was also the case if
multiple bands were obtained in PCR amplifications using a
single cDNA source. Sequencing different fragments obtained for
a specific TFU allowed us to characterize a number of alterna-
tively spliced transcripts. Sequencing reactions were carried out
by using the DYEnamic ET terminator Cycle Sequencing Kit (Am-
ersham Pharmacia) and separated by electrophoresis using an
ABI 377 Prism Sequencer (Applied Biosystems) according to sup-
plier’s recommendations.
Transcriptome Database and Graphical Interface
BLASTN was used to identify pair-wise similarities between all
known transcript sequences and the draft genome sequence de-
posited in release 66 (March 2001) of the European Molecular
Biology Laboratory (EMBL) database. Transcribed sequence data
were extracted from several sources: (1) the human EST section of
EMBL release 66, (2) human mRNA documented in the human
section of EMBL release 66, (3) ORESTES sequences from the Lud-
wig Institute for Cancer Research (LICR)/FAPESP Human Cancer
Genome project, and (4) human mRNAs documented in the
NCBI curated RefSeq database (http://www.ncbi.nlm.nih.gov/
refseq). For genomic sequence, we used contigs of at least 10 kb
deposited in the HUM and HTG sections. Those HTG entries that
had not been fully assembled were split into individual compo-
nents. Therefore, the human genome data set used is highly redun-
dant but can easily be reduced to one of the available assemblies.
The transcript sequences were filtered for contaminants,
and repetitive elements were masked out by using the PFP soft-
ware package (Paracel). For each pair of matching transcribed and
genomic sequences, local alignments were generated by using
Sim4 (Florea et al. 1998), with parameters W = 15, R = 0, A = 4,
and P = 1. The output of Sim4 was filtered to eliminate all align-
ments that did not contain at least one matching region within
the genome with at least 95% identity over 30 nt. The alignment
coordinates and related information were uploaded into a
MySQL relational database. We used the data stored in the rela-
tional database to create clusters of transcribed sequences, based
on their position within individual genomic contigs. The coor-
dinates of the putative exons on the genome sequence were used
to determine membership in a cluster. If coordinates of at least
one exon were common to two transcripts, then these were con-
sidered to be part of the same cluster.
The 3 tags were generated as previously described (Iseli et al.
2002). Briefly, poly(A) or poly(T) were identified from original
sequence trace files, and the 50 nucleotides immediately adjacent
to it were recorded as a candidate tag (after obtaining the reverse
complement for poly(T) tracts). Duplicate tags were eliminated,
as were the tags matching LINE and Alu repetitive elements, ri-
bosomal or mitochondrial sequences, and those containing
simple repeats. Matches for the remaining tags were mapped to
the genome, and the 50 nucleotides found downstream of the
match were also recorded. Individual tags were incorporated into
the MySQL database. A graphical interface was developed in TCL/
TK language in order to visualize the 3 tags, EST alignments and
related information, such as tissue origin and project source of
the sequences.
By querying the transcriptome database, we were able to
select EST clusters that do not correspond to known full-length
mRNA for validation. These were at a maximum of 10 kb apart
from each other and exhibited a clear splicing structure when
aligned to the genome. Clusters selected for validation were vi-
sually inspected before ordering primers. All systems used in this
work were developed by using PERL and PHP programming lan-
guages on a Linux-based server running the MySQL database
management system and the Apache Web server.
Cluster Selection and Primers Design
The automated primer protocol received a fixed format file con-
taining the accession number of the genomic clones and the
Figure 4 Experimental validation of MGC5601 gene alternative splicing isoforms. (A) Gene structure for exons XVI-XIX (boxes) of the MGC5601 gene
located on chromosome 12. Introns are represented by lines. Two alternative exons are shown on TFU reads, and a hypothetical combination of these
two exons is also shown. Sequence F07R has an extra exon between exon XVII and XVIII. Sequence A01R has an extended exon XIX. Four primers were
designed for validation tests, as indicated in the figure (P1–P4), and each pair of primers were assayed against all 22 cDNA preparations without pooling.
(B) We detected all four of these alternative splicing isoforms in MGC5601. Numbers one through four indicate the tissues from which the cDNA was
obtained (1, multiform glioblastoma; 2, glioblastoma; 3, prostate carcinoma; and 4, primary kidney cell culture). The sizes of the bands obtained are
indicated. L indicates 100-bp ladder.
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genomic interval where the two noncontiguous EST clusters map
and where the system searched for primers. A single pair of prim-
ers was designed for each TFU, which usually targeted the two
exons flanking the putative gap. In a few cases, in which the
presence of repetitive sequences or atypical base composition
prevented the design of primers, adjacent exons were used. The
Primer3 program (version 0.9) developed by the Whitehead In-
stitute for Biomedical Research was used for primer design,
adopting the following parameters: primer size of a minimum of
17 bp, optimal 18 bp and maximum 21 bp; melting temperature
of a minimum of 55°C, optimal 60°C and maximum 65°C; and
GC clamp set to one. The output of Primer3 was processed in
order to filter primers that had alternate annealing sites in the
given genomic sequence. The system uses a Web-based interface
that allows submission of files containing information on primer
design, retrieval of primers found, and the modification of de-
fault parameters for primer picking.
Sequence Analysis and Database Update
Sequences were subjected to an automated protocol to (1) assess
sequence quality, (2) trim vector sequences, (3) mask repetitive
elements, and (4) remove undesirable sequences such as bacte-
rial, mitochondrial, and fungi sequences. The sequence quality
was determined by Phred analysis using a trimCutOff of 0.06171
(Ewing and Green 1998; Ewing et al. 1998). Sequences with <100
bases were excluded. Mitochondrial, bacterial, and fungi se-
quences were identified by BLAST searches against the GenBank
entry corresponding to the human mitochondrial complete ge-
nome sequence and against a locally developed bacterial and
fungal database, respectively. Significant hits were determined by
using an E value of 105 for searches against mitochondrial ge-
nome and an E value of 1030 for searches against bacterial da-
tabases. Masking of repetitive elements was undertaken by using
the RepeatMasker (http://www.repeatmasker.org) under default
parameters. The remaining high-quality sequences were aligned
against the original genomic clone by using the BLASTN pro-
gram, and alignment coordinates and scores were loaded into the
MySQL database on a daily basis.
Consensus Assembly
The reads corresponding to validated TFs were assembled into
a contig by using the PhredPhrap. The contig sequence was
aligned with both EST clusters by using the BLASTN program,
and alignment coordinates were used for consensus generation.
A Web-based interface was developed to monitor the assembly
and access the consensus sequences (http://200.18.51.201/
viewconsensus/).
Characterization of Validated Transcripts
Characterization of validated transcripts was pursued by using
the UCSC Genome Browser (Kent et al. 2002), which is available
at http://genome.ucsc.edu. This allowed determination of se-
quence overlap between the validated consensus sequences,
known genes, and gene predictions. Consensus sequences de-
rived from the validated TFUs were aligned to the July 2003 ver-
sion of the human genome sequence assembly provided by
UCSC using the BLAT search tool. The annotation tracks used for
comparison to already known genes were known genes, RefSeq
genes, and human mRNAs from the GenBank. A validated tran-
script was considered a new gene if its alignment coordinates did
not match the coordinates of any other sequence available
through the known genes, RefSeq genes, or human mRNA anno-
tation tracks. For comparison to gene predictions, the following
tracks were used: Fgenesh++, Geneid, and GenScan predictions.
The prediction of individual exons instead of the full transcript
prediction was considered. A validated exon was considered as
predicted if it aligned within the coordinates defined by any of
the three gene prediction programs (not necessarily sharing bor-
ders) and a new validated transcript was considered not predicted
if all exons were not predicted by the computer programs. The
consensus sequences corresponding to new validated transcripts
were further characterized by BLASTX analysis, and protein do-
mains were determined by using the Pfam and Prosite databases.
Characterization and Validation of Alternatively
Splicing Forms
The individual sequences generated during the process of valida-
tion of each TFU were aligned to the human genome assembly by
using the BLAT search tool, together with the final consensus
sequence and representative sequences derived from both EST
clusters. Alternatively spliced isoforms were visually identified by
using the UCSC browser. To eliminate alignment artifacts caused
by sequencing errors and problems in the genome assembly, we
have considered as alternatively spliced forms only exons de-
fined by conserved acceptor and donor splicing sites (GT/AG).
Primers for validation of predicted alternative splicing isoforms
were designed by using Primer3 with default parameters. The
presence of alternative isoforms was analyzed by using a cDNA
panel composed of 20 different normal and tumor tissues. GAPD
amplification was used as a control for integrity and quantifica-
tion of the RNA used for cDNA synthesis. RT-PCR products ob-
tained in touchdown reactions were analyzed on 1.5% agarose gels.
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